Earnings summaries and quarterly performance for CHEMED.
Executive leadership at CHEMED.
Kevin J. McNamara
Detailed
President and Chief Executive Officer
CEO
BC
Brian C. Judkins
Detailed
Vice President, Secretary and Chief Legal Officer
MD
Michael D. Witzeman
Detailed
Chief Financial Officer, Vice President and Controller
NM
Nicholas M. Westfall
Detailed
Executive Vice President
SS
Spencer S. Lee
Detailed
Executive Vice President
Board of directors at CHEMED.
Research analysts who have asked questions during CHEMED earnings calls.
JG
Joanna Gajuk
Bank of America
6 questions for CHE
Also covers: ACHC, ADC, ADUS +22 more
Benjamin Hendrix
RBC Capital Markets
5 questions for CHE
Also covers: ACHC, ADUS, AHCO +25 more
Brian Tanquilut
Jefferies
5 questions for CHE
Also covers: ACHC, ADUS, AHCO +31 more
BH
Ben Hendricks
RBC Capital Markets
2 questions for CHE
Also covers: ACHC, ADUS, BKD +11 more
Christian Malachy Porter
Bank of America
1 question for CHE
Also covers: DVA, EHC, SEM
MM
Michael Murray
RBC Capital Markets
1 question for CHE
Also covers: ADUS, AHCO, AMED +8 more
Recent press releases and 8-K filings for CHE.
Chemed Reports Q4 2025 Results and Provides 2026 Guidance
CHE
Earnings
Guidance Update
Demand Weakening
- Chemed Corporation's fourth quarter of 2025 fell short of expectations for both VITAS and Roto-Rooter, with 2026 anticipated as a transition year for both subsidiaries.
- VITAS net revenue increased 1.9% to $418.8 million in Q4 2025, and management is confident the Florida Medicare cap problem of 2025 is behind them, with a strategic rebalancing of admissions expected to build revenue and EBITDA margins over 2026.
- Roto-Rooter revenue declined 3.7% in Q4 2025 due to increased water restoration write-offs and flat total leads, but the company forecasts 3%-3.5% revenue growth for 2026 based on improved lead volume and centralized billing processes.
- Chemed estimates full-year 2026 adjusted earnings per diluted share to be in the range of $23.25-$24.25, up from $21.55 in 2025, with 55% of consolidated adjusted net income and EBITDA projected to be generated in the second half of the year.
7 days ago
Chemed Corporation Reports Q4 2025 Results and Provides 2026 Guidance
CHE
Earnings
Guidance Update
Share Buyback
- Chemed Corporation's fourth quarter 2025 results fell short of expectations for both its VITAS and Roto-Rooter subsidiaries.
- VITAS reported net revenue of $418.8 million, a 1.9% increase from the prior year period, and adjusted EBITDA of $91.6 million, a 1.7% decline, in Q4 2025. Admissions increased 6% compared to the same period in 2024, and management is confident that the Florida Medicare cap problem of 2025 is resolved.
- Roto-Rooter's revenue declined 3.7% in Q4 2025 compared to the prior year, with adjusted EBITDA decreasing 21.1% to $47.5 million due to higher marketing costs and increased water restoration write-offs.
- For full year 2026, Chemed estimates adjusted earnings per diluted share to be in the range of $23.25-$24.25, up from $21.55 in 2025, with 55% of the consolidated adjusted net income and EBITDA projected to be generated in the second half of the year.
- During Q4 2025, the company repurchased 400,000 shares of Chemed stock at an average price of $436.39.
7 days ago
Chemed Corporation Reports Q4 2025 Results and Provides 2026 Guidance
CHE
Earnings
Guidance Update
Demand Weakening
- Chemed Corporation reported that Q4 2025 results fell short of expectations for both subsidiaries, leading to a $0.70 per share miss.
- VITAS Healthcare saw admissions increase 6% in Q4 2025 compared to Q4 2024, but revenue growth and EBITDA margin were lower due to a higher mix of short-stay patients. The Florida Medicare cap issue from 2025 is now considered resolved.
- Roto-Rooter's Q4 2025 revenue declined 3.7% and adjusted EBITDA decreased 21.1% to $47.5 million, primarily due to increased water restoration write-offs and higher marketing costs.
- For full year 2026, Chemed projects adjusted earnings per diluted share of $23.25-$24.25, up from $21.55 in 2025, with 55% of consolidated adjusted net income and EBITDA expected in the second half.
- 2026 guidance includes VITAS revenue growth of 5.5%-6.5% and Roto-Rooter revenue growth of 3%-3.5%. The company repurchased 400,000 shares at an average price of $436.39 in Q4 2025.
7 days ago
Chemed Reports Q4 2025 Results and Provides 2026 Guidance
CHE
Earnings
Guidance Update
Share Buyback
- Chemed reported Q4 2025 consolidated revenue of $639.3 million, which was essentially flat compared to the prior-year period, with GAAP Diluted EPS of $5.48 (a 9.0% decrease) and Adjusted Diluted EPS of $6.42 (a 6.0% decrease).
- The VITAS segment recorded Net Patient Revenue of $418.8 million, an increase of 1.9%, and Admissions of 17,419, an increase of 6.0% in Q4 2025. In contrast, the Roto-Rooter segment experienced a 3.7% decrease in revenue to $220.6 million and a 21.1% decline in Adjusted EBITDA to $47.5 million.
- For full-year 2026, Chemed estimates Adjusted Diluted EPS to be in the range of $23.25 to $24.25. This guidance includes projected VITAS revenue growth of 5.5% to 6.5% and Roto-Rooter revenue growth of 3.0% to 3.5%.
- As of December 31, 2025, Chemed had $74.5 million in cash and cash equivalents and no current or long-term debt. During Q4 2025, the company repurchased 400,000 shares of its stock for $174.6 million.
8 days ago
Chemed Reports Fourth-Quarter 2025 Results and Issues 2026 Guidance
CHE
Earnings
Guidance Update
Share Buyback
- Chemed Corporation reported Q4 2025 consolidated revenue of $639.3 million, which was essentially flat compared to the prior-year period, with GAAP diluted EPS of $5.48 (a 9.0% decrease) and Adjusted diluted EPS of $6.42 (a 6.0% decrease).
- The VITAS segment's net patient revenue increased by 1.9% to $418.8 million, and admissions rose by 6.0% to 17,419 in Q4 2025, while the Roto-Rooter segment's revenue decreased by 3.7% to $220.6 million.
- During the fourth quarter of 2025, Chemed repurchased 400,000 shares for $174.6 million, leaving $127.3 million in remaining share repurchase authorization as of December 31, 2025. The company had $74.5 million in cash and cash equivalents and no current or long-term debt as of the same date.
- For the full-year 2026, Chemed estimates adjusted diluted EPS to be in the range of $23.25 to $24.25, with VITAS revenue (prior to Medicare Cap) projected to increase 5.5% to 6.5% and Roto-Rooter revenue growth forecasted at 3.0% to 3.5%.
8 days ago
Chemed Board Authorizes Additional Share Repurchase and Declares Quarterly Dividend
CHE
Share Buyback
Dividends
- Chemed Corporation's Board of Directors has authorized an additional $300 million for its existing share repurchase program.
- The company declared a quarterly cash dividend of 60-cents per share, payable on March 13, 2026, to shareholders of record as of February 23, 2026.
- This represents the 219th consecutive quarterly dividend paid by Chemed.
Feb 13, 2026, 6:20 PM
Chemed Provides Business Update on VITAS and Roto-Rooter Segments
CHE
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Chemed operates two distinct service businesses: VITAS (hospice provider) and Roto-Rooter (plumbing and drain care). Historically, both businesses delivered consistent net income growth of 11-12% per annum, with strong cash flow used to repurchase over $2 billion of Chemed stock, leading to an 18% per annum stock price growth over 20 years.
- VITAS faced a $18.9 million Medicare cap limitation in Florida for the 2025 Medicare cap year (which began in Q4 2024), but this is considered a one-time event and is not anticipated to recur in 2026 due to strategic mitigation efforts, including shifting focus back to hospital admissions.
- Roto-Rooter experienced intense competition, particularly from private equity-backed companies in Google advertising, which led to double-digit declines in phone calls over the past two years; however, the competitive environment is now showing signs of improvement.
- VITAS expects to return to 4-5% growth rates, with potential for high single-digit to low double-digit top-line growth in the foreseeable future, and anticipates no significant labor headwinds for 2026.
- Roto-Rooter is expanding its commercial business manager program, which has demonstrated a 20% revenue increase in the 15 branches where it has been implemented, with plans to expand this program to almost all branches in 2026.
Nov 11, 2025, 7:00 PM
Chemed Corporation Reports Q3 2025 Results and Reaffirms Guidance
CHE
Earnings
Guidance Update
Demand Weakening
- Chemed Corporation reaffirmed its 2025 guidance of $22 to $22.30 per share, excluding non-cash expenses for stock options, tax benefits, litigation costs, and other discrete items.
- VITAS Healthcare reported Q3 2025 net revenue of $407.7 million, a 4.2% increase year-over-year, driven by a 2.5% increase in days of care and a 4.1% Medicare reimbursement rate increase. Admissions totaled 17,714, a 5.6% improvement from the prior year, with hospital-based admissions at 44.5%. Management anticipates no Medicare cap billing limitation for its Florida program in 2026.
- Roto-Rooter revenue increased 1.1% in Q3 2025, with branch residential revenue up 3.4% and commercial revenue up 2.8%. However, revenue from independent contractors declined 4.7%. Adjusted EBITDA for Roto-Rooter was $49.4 million, a 12.4% decrease from the prior year, with an adjusted EBITDA margin of 22.7%. The shift from unpaid to paid leads resulted in a $3.6 million increase in SG&A costs.
- Management expects seasonal improvements in Q4 2025 for both segments and projects VITAS 2026 revenue growth in the 8% range with margins of 17.5% to 18%, while Roto-Rooter targets long-term EBITDA margins of 25% to 26%.
Oct 29, 2025, 2:00 PM
Chemed Corporation Announces Q3 2025 Results
CHE
Earnings
New Projects/Investments
- Chemed Corporation reported Service Revenues and Sales of $1,890,641 thousand for the nine months ended September 30, 2025, marking a 5.5% increase compared to the same period in 2024.
- Despite revenue growth, Chemed's Adjusted EBITDA for the nine months ended September 30, 2025, decreased by 8.8% to $326,070 thousand, and Adjusted Diluted EPS declined by 7.1% to $15.16 for the same period.
- VITAS, a segment of Chemed, generated $407,741 thousand in revenue after Medicare Cap Reduction in Q3 2025, with an Average Daily Census (ADC) of 22,327 and an Average Length of Stay (ALOS) of 109.7 days.
- For the nine months ended September 30, 2025, VITAS's Net Service Revenues and Sales increased by 8.2% to $1,211,341 thousand, while its Adjusted EBITDA decreased by 6.2% to $182,703 thousand.
- Roto-Rooter's Service Revenues and Sales for the nine months ended September 30, 2025, grew by 1.2% to $679,300 thousand, but its Adjusted EBITDA decreased by 11.1% to $157,212 thousand.
Oct 29, 2025, 2:00 PM
Chemed Reports Q3 2025 Results with VITAS Revenue Growth and Roto-Rooter Margin Pressures
CHE
Earnings
Guidance Update
Revenue Acceleration/Inflection
- VITAS Healthcare reported net revenue of $407.7 million in Q3 2025, a 4.2% increase compared to the prior year period, primarily due to a 2.5% increase in days of care and a 4.1% Medicare reimbursement rate increase.
- Management anticipates no Medicare cap billing limitation for its Florida program in 2026, despite accruing $6.1 million in Q3 2025, contributing to an estimated $18.9 million for the 2025 Medicare cap year. This confidence is supported by 44.5% of Q3 2025 admissions coming from hospitals, within the target range of 42%-45%.
- Roto-Rooter's revenue increased 1.1% in Q3 2025, with branch residential revenue up 3.4% and commercial revenue up 2.8%, though revenue from independent contractors declined 4.7%.
- Roto-Rooter's adjusted EBITDA decreased 12.4% to $49.4 million, resulting in an adjusted EBITDA margin of 22.7%, largely due to a $3.6 million increase in SG&A costs from the shift to paid leads. Management expects margin improvements and 3% to 5% top-line growth for Roto-Rooter in 2026.
Oct 29, 2025, 2:00 PM
Quarterly earnings call transcripts for CHEMED.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more